Biotechnology

A Right Pain in the Peripheries? The Supreme Court Decision in Warner-Lambert v Generics & Actavis

Summary In a significant judgment, the UK Supreme Court has rejected Warner-Lambert’s appeal against the revocation of patent EP(UK) No. 0934061, for the use of pregabalin in the treatment of pain. A key part of the ruling was the upholding of the appeal decision that a higher threshold of plausibility...

Read more

Wisdom of the crowd: how to make sure IP doesn’t derail your crowdfunding efforts

Startups raising hundreds of thousands – even millions – of pounds via Kickstarter may be rarer than it once was, but crowdfunding remains a popular method of fundraising. There are a myriad of options, whether you go down the equity crowdfunding route offered by the likes of Seedrs, CrowdCube, and...

Read more

In a new age of personalised cancer therapy, is patent law in Europe still fit for purpose?

In the last week it has been announced that the NHS has struck a deal with Novartis to offer their ground-breaking new CAR-T therapy, Kymriah®, to paediatric patients with B cell acute lymphoblastic leukaemia. This is a significant development and means that some patients will now have access to this...

Read more

Asking the right questions to optimise life sciences IP

This article was originally published on Biotech and Money. Supporting commercial goals by asking ‘why?’ As there is no one-size-fits-all approach to developing an effective IP strategy, GJE ensures it has a thorough understanding of its clients’ objectives and developments within their businesses so that it is able to offer the...

Read more

The growth finance landscape in biotech

Ian Jones took the helm of a lively panel debate at the Biotech and Money/Medtech and Money World Congress 2018 on the continued influence of venture capital on the sector and their appetite for growth and follow-on investment. Speaking on the panel were the following venture capital and corporate venturing...

Read more